TW-37 is an inhibitor of the Bcl-2 family proteins Bcl-2, Mcl-1, and Bcl-xL (Kis = 120, 260, and 1,100 nM, respectively). It induces apoptosis, inhibits migration and capillary sprouting, and blocks the expression of the angiogenic chemokines CXCL1 and CXCL8 in endothelial cells. TW-37 decreases the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis when administered intravenously. It has apoptotic action against leukemia, lymphoma, and pancreatic cancer cells.
TW-37 is a Bcl-2 inhibitor that suppresses growth and enhance cisplatin-induced apoptosis in ovarian cancer cells. Also functions as an MCL-1 inhibitor that kills many more malignant cells.
TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM, respectively.
ChEBI: N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide is a member of benzamides.
A murine model of humanized vasculature is used to investigate the biological effect of TW-37 (TW37) on human microvascular endothelial cell in vivo. Using this model, a significant decrease is observed in total blood vessel number (P<0.05) comparing both 3 and 30 mg/kg TW-37 against vehicle control. In addition to reduction in total number of blood vessels, an unusual number of occluded vessels are occurring in the treated groups. The levels of vessel occlusion are assessed by counting completely blocked vessels and determining their number as a percentage of total vessel number. TW-37 concentration mediates a significant increase in the number of occluded vessels when compared with control[1].
Mcl-1: 260 nM (Ki); Bcl-2: 290 nM (Ki); Bcl-xL: 1110 nM (Ki)
[1] MONIQUE VERHAEGEN. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.[J]. Cancer research, 2006, 66 23: 11348-11359. DOI:
10.1158/0008-5472.can-06-1748[2] BENJAMIN D ZEITLIN. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2.[J]. Cancer research, 2006, 66 17: 8698-8706. DOI:
10.1158/0008-5472.can-05-3691[3] ASFAR S. AZMI Ramzi M M. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy[J]. Journal of Cellular Physiology, 2008, 218 1: 13-21. DOI:
10.1002/jcp.21567
